Lv21
154 积分 2023-10-17 加入
Frequency of infusion-related reactions with CPX-351 treatment in an observational study in adults with newly diagnosed therapy-related AML or AML with myelodysplasia-related changes (AML-MRC)
1小时前
已完结
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
4小时前
已完结
CPX-351 (Vyxeos) in Acute Myeloid Leukemia: Time to Move on?
2天前
已完结
A Phase 2 Trial of CPX-351 Combined With Venetoclax in Relapsed or Refractory Acute Myeloid Leukemia
17天前
已完结
Venetoclax and decitabine vs intensive chemotherapy as induction for young patients with newly diagnosed AML
30天前
已完结
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
1个月前
已完结
Cladribine Added to Idarubicin and Cytarabine as an Induction Regimen for Patients with De Novo Acute Myeloid Leukemia: A Multicenter, Randomized Phase III Trial
1个月前
已完结
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
1个月前
已完结
Advances in menin inhibition in acute myeloid leukemia
1个月前
已完结
Venetoclax plus '2 + 5' modified intensive chemotherapy with daunorubicin and cytarabine in fit elderly patients with untreated de novo acute myeloid leukaemia: a single-centre retrospective analysis
1个月前
已完结
皖公网安备34019202002308
